News articles about OraSure Technologies (NASDAQ:OSUR) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.9277396136826 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- BidaskClub Downgrades OraSure Technologies (OSUR) to Hold (americanbankingnews.com)
- OraSure Technologies (OSUR) Lowered to Hold at Jefferies Group (americanbankingnews.com)
- Edited Transcript of OSUR earnings conference call or presentation 7-Feb-18 10:00pm GMT (finance.yahoo.com)
- Global HIV/AIDS Diagnostics Market 2018 – OraSure Technologies, Abbott Laboratories, Bio-Rad, Hologic, Chembio … (healthcaretrends24.com)
- OraSure Technologies, Inc. (NASDAQ:OSUR) – An Eye on Stock’s Liquidity (nasdaqjournal.com)
OSUR traded up $0.19 during trading on Tuesday, reaching $16.84. 702,359 shares of the company’s stock were exchanged, compared to its average volume of 667,658. OraSure Technologies has a fifty-two week low of $12.02 and a fifty-two week high of $23.01. The firm has a market capitalization of $1,029.73, a PE ratio of 33.02, a P/E/G ratio of 5.00 and a beta of 1.65.
A number of research analysts have commented on OSUR shares. Canaccord Genuity restated a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a research note on Friday, February 2nd. BidaskClub upgraded shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Friday, February 9th. Finally, ValuEngine upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $22.25.
In related news, Director Stephen S. Phd Tang sold 23,333 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $17.97, for a total value of $419,294.01. Following the sale, the director now directly owns 59,749 shares of the company’s stock, valued at approximately $1,073,689.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brian Smith sold 20,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $17.97, for a total transaction of $359,400.00. Following the completion of the sale, the executive vice president now directly owns 28,075 shares in the company, valued at $504,507.75. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.